| Field | Specification |
|---|---|
| Mfr No | |
| Product Type | |
| Shipping | |
| Source | Recombinant (E. coli) |
| Storage |
UltraNuclease, also known as non-specific nuclease or broad-spectrum nuclease, is a non-specific endonuclease derived from Serratia Marcescen. It can cleave at any nucleotide within the chain, completely digesting nucleic acids into 5'-monophosphate oligonucleotides of 2-5 bases in length. UltraNuclease is capable of degrading various forms (double-stranded, single-stranded, linear, circular, native, or denatured) of DNA and RNA under a wide range of conditions (6 M Urea, 0.1 M Guanidine HCl, 0.4% Triton X-100, 0.1% SDS, 1 mM EDTA, 1 mM PMSF). It is widely used for removing nucleic acids from biological products.
This product is genetically engineered and expressed in Escherichia coli (E. coli), with a purity ≥99%. It is used to reduce the viscosity of cell supernatants and cell lysates, improve protein purification efficiency and functionality studies, and effectively prevent the clumping of human peripheral blood mononuclear cells (PBMCs) in cell therapy and vaccine research.
It is provided as a sterile liquid enzyme stored in buffer (20 mM Tris-HCl pH 8.0, 2 mM MgCl2, 20 mM NaCl, 50% Glycerol), appearing as a clear, colorless liquid.
Features
Wide range of applications: degrade all forms of DNA and RNA
High purity and activity: purity ≥ 99%; specific activity ≥ 1.5×106 U/mg
Specification
|
Source |
E. coli |
|
Molecular Weight |
26.5 kDa |
|
Isoelectric Point |
6.85 |
|
Purity |
≥ 99%（HPLC） |
|
Enzyme Activity |
250-300 U/μL |
|
Specific Activity |
≥1.5×106 U/mg protein |
|
Optimum pH |
8.0 (pH range 6-10) |
|
Optimum Temperature |
37°C (temperature range 0-42°C) |
|
Cofactor |
1-10 mM Mg2+ |
|
Storage Buffer |
20 mM Tris-HCl pH8.0，2 mM MgCl2，20 mM NaCl，50% Glycerol |
| Glycerol Content: Contains Glycerol |
Store this enzyme at -20°C and avoid repeated freeze-thaw cycles to preserve catalytic activity. The product is shipped Dry Ice and remains stable for up to one year from the date of manufacture when stored under recommended conditions. Aliquoting the stock solution into single-use volumes is recommended for enzymes used infrequently to minimize thermal cycling of the bulk stock.
This enzyme is validated for use in Nucleic Acid Purification applications. It is suitable for use in both standard laboratory research settings and, where applicable, optimized reaction workflows requiring high specificity, sensitivity, or throughput.
One unit (U) is defined as the amount of enzyme that degrades 1 µg of DNA or RNA substrate to acid-soluble form in 30 min at 37°C under defined buffer conditions.
This enzyme is produced as Recombinant (E. coli) and supplied as a Research Use Only (RUO) reagent. Each lot is subjected to activity assay, purity assessment by SDS-PAGE, and functional validation prior to release. A Certificate of Analysis (CoA) and Safety Data Sheet (SDS) are available on request.
Nuclease activity typically requires divalent metal ion cofactors (Mg²⁺ or Mn²⁺ at 1–5 mM). Activity is inhibited by chelating agents such as EDTA (≥1 mM), high salt concentrations, and reducing agents such as DTT at elevated concentrations. Heat inactivation (65–75°C for 15 min) is effective for most nucleases, allowing removal of enzyme activity after digestion without column purification.
Yeasen Biotechnology supports custom enzyme solutions across multiple service lines — from GMP-grade bulk supply to directed enzyme engineering. Contact BioHippo to discuss requirements and initiate a project inquiry.
▶ GMP-Grade & Bulk Supply
Select Yeasen enzymes are available in GMP grade, manufactured in an ISO 13485-certified UCF.ME™ ultra-clean molecular enzyme facility with FDA Drug Master File (DMF) support.
- GMP-grade release testing and CoA documentation
- ISO 13485-certified production facility
- Scalable from milligram to multi-gram quantities
- Consistent lot-to-lot activity specifications
▶ Glycerol-Free & Custom Formulation
Glycerol-free enzyme formats are available for applications requiring lyophilization compatibility, liquid handling automation, or direct IVD master mix integration.
- Glycerol-free liquid format (standard and custom buffers)
- Lyophilization-ready enzyme preparation
- Custom reaction buffer optimization for specific assay conditions
- Compatible with freeze-drying workflows for point-of-care formats
▶ Molecular IVD RDC Service
Yeasen's Research and Development Contracting (RDC) team delivers end-to-end solutions for molecular diagnostic product development, covering enzyme selection through clinical validation support.
- Enzyme selection and performance matching
- Primer/probe design and reaction buffer optimization
- Sensitivity, specificity, and precision validation studies
- Stability studies and SNP evaluation
- Instrument platform compatibility assessment
▶ ZymeEditor™ Enzyme Engineering
Yeasen's proprietary ZymeEditor™ directed evolution and rational design platform enables the development of custom enzyme variants with tailored performance characteristics not available in off-the-shelf products.
- Directed evolution for enhanced thermostability, processivity, or fidelity
- Rational design for altered substrate specificity or cofactor requirements
- Library screening from Yeasen's proprietary enzyme variant collection
- Scale-up to commercial quantities upon candidate confirmation
ⓘ Customization services are fulfilled by Yeasen Biotechnology. Lead times and minimum order quantities vary by service type. Contact BioHippo for project scoping and pricing.
- Lin J, Chen Z, Yang L, et al. Cas9/AAV9-Mediated Somatic Mutagenesis Uncovered the Cell-Autonomous Role of Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 in Murine Cardiomyocyte Maturation. Front Cell Dev Biol. 2022;10:864516. Published 2022 Apr 1. doi:10.3389/fcell.2022.864516(IF:6.684)
- Kang D, Liu Y, Song Y, Fang B, Zhang Q, Hu L. Triptolide Shows High Sensitivity and Low Toxicity Against Acute Myeloid Leukemia Cell Lines Through Inhibiting WSTF-RNAPII Complex. Front Oncol. 2022;12:811850. Published 2022 Feb 16. doi:10.3389/fonc.2022.811850(IF:6.244)
